Cinacalcet
- Generic Name
- Cinacalcet
- Brand Names
- Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22F3N
- CAS Number
- 226256-56-0
- Unique Ingredient Identifier
- UAZ6V7728S
- Background
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
- Indication
For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
- Associated Conditions
- Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
- Conditions
- HypercalcemiaHyperparathyroidism, Primary
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT00975221
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2009-08-04
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT00952094
- Locations
- 🇰🇷
Seoul National University Hospital Clinical Trial Center, Seoul, Korea, Republic of
A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 78
- Registration Number
- NCT00936650
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT00936988
PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 305
- Registration Number
- NCT00928408
Calcimimetics in Hypophosphatemic Rickets
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Registration Number
- NCT00844740
- Locations
- 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
20070360 Incident Dialysis
- Conditions
- Secondary HyperparathyroidismChronic Kidney Disease
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 313
- Registration Number
- NCT00803712
Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2009-01-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 320
- Registration Number
- NCT00527267
12-month Study of AMG 073 in Renal Osteodystrophy
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT00527085
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
- Conditions
- Secondary Hyperparathyroidism
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Papageorgiou General Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00446329
- Locations
- 🇬🇷
Papageorgiou General Hospital, Thessaloniki, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.